| |
|
| |
|
|
Frank Meyskens, MD, PhD
Daniel G. Aldrich Jr. Endowed Professor, Medicine and Biological Chemistry, UC Irvine
Associate Vice Chancellor, College of Health Sciences, UC Irvine
Director, Chao Family Comprehensive Cancer Center, UC Irvine
|
| |
| Current PI funding: NIH/NCI (N01-CN-35160), Clinical trials of chemopreventive agents (2003-2010)
NIH/NCI (P30-CA-62203), Cancer Center support grant (2002-2009)
NIH/NCI (R01-CA-88078), DFMO plus Sulindac to prevent colon cancer (2002-2009)
NIH/NCI (U01-CA-72294), Bowman-Birk inhibitor and oral leukoplakia (2004-2009) |
| |
| Mentoring: As director of UC Irvine's distinguished Comprehensive Cancer Center, Dr. Meyskens has extensive experience training and mentoring clinician-investigators in basic and applied research on the diagnosis and treatment of cancer. For example his former student Dr. Debra Saxe is now Director of the Oncology Cytogenetics Laboratory at Emory University. Dr. Meyskens has mentored 45 trainees and is training 3 post-docs currently. In 2006 Dr. Meyskens received the Distinguished Career Achievement Award from the American Society of Preventive Oncology. |
| |
| Research: Dr. Meyskens is internationally known for his research work in two major areas—the clinical chemoprevention of human cancer, and basic and clinical studies of human melanoma. The long term interest of Dr. Meyskens' laboratory has been the development of experimental and clinical therapies based on knowledge of the transformation process in the cell type. Current efforts are focused on characterizing the role of the redox-sensitive transcription factors NFKB and AP-1 on regulating cell growth and the effects of antioxidants, redox mimetic, NFKB inhibitors, and apoptosis and chemoprevention of human cancer. Co-author of more than 400 peer-reviewed journal articles, Dr. Meyskens was the Inaugural Salmon Awardee in Translational Research, 2006 (Arizona Cancer Center). |
|
|
